Rigel Pharmaceuticals (RIGL) Receivables (2013 - 2026)

Rigel Pharmaceuticals has reported Receivables for 13 years, with the latest figure at $50.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 1566.5% year-over-year to $50.9 million; the trailing twelve-month figure through Mar 2026 stood at $50.9 million (up 1566.5% YoY), and the FY2025 full-year result was $52.7 million, up 26.55% from the prior year.
• Receivables for Q1 2026 stood at $50.9 million, down from $52.7 million in the prior quarter.
• The five-year high for Receivables was $52.7 million in Q4 2025, with the low at $3.1 million in Q1 2025.
• Average Receivables over 5 years is $29.0 million, with a median of $28.9 million recorded in 2024.
• Year-over-year, Receivables slumped 89.28% in 2022 and soared 1566.5% in 2026.
• Tracing RIGL's Receivables over 5 years: stood at $20.0 million in 2022, then surged by 52.75% to $30.6 million in 2023, then jumped by 36.22% to $41.6 million in 2024, then grew by 26.55% to $52.7 million in 2025, then retreated by 3.26% to $50.9 million in 2026.
• The last three Receivables figures came in at $50.9 million (Q1 2026), $52.7 million (Q4 2025), and $46.0 million (Q3 2025), per Business Quant data.

Peer Comparison